ADIPOQ and Alzheimer disease: Because the average age of AD patients was smaller than that of non-AD patients (78.5 vs. 86.3 years old) (Supplementary Table 2), CSF adiponectin levels of only patients aged 81–88 years old were compared (Supplementary Table 3), to exclude the effect of the age imbalance between AD and non-AD groups on the result.